(Q28541955)

English

Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy (English)

0 references

Hong-chiang Chang

object named as

Hong-Chiang Chang

5

0 references

object named as

Ju-Ton Hsieh

2

0 references

object named as

Kuo-How Huang

3

0 references

object named as

Yeong-Shiau Pu

4

0 references

author name string

Chien-Hua Chen

1

0 references

language of work or name

0 references

publication date

2014

0 references

0 references

9

0 references

8

0 references

e105091

0 references

copyright license

Creative Commons Attribution 4.0 International

14 August 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

7 April 2017

Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

How is androgen-dependent metastatic prostate cancer best treated?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

29 September 2017

PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

3 June 2018

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

3 June 2018

Prognostic factors in patients with advanced stage prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

3 June 2018

Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

3 June 2018

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4133301

3 June 2018

Serum prostate‐specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive Partitioning

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0105091

21 January 2018

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-Specific Antigen Density Predicts Adverse Pathology and Increased Risk of Biochemical Failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25121948

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0105091

0 references

2014PLoSO...9j5091C

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28541955&oldid=1860862078"